rethinkTHC Search
Menu
Study breakdown

Cannabinoids Show Anti-Cancer Potential in Lab Studies, but Results Remain Contradictory

ReviewPreliminary evidence
The takeaway

A critical review found growing evidence that various cannabinoids can kill cancer cells in laboratory and animal studies across multiple cancer types, but contradictory results and uncertain mechanisms limit conclusions.

Read this if you have heard claims about cannabis and cancer and want to understand what the laboratory evidence actually shows.

Both pro- and anti-tumor cannabinoid effects documented depending on conditions

What the researchers found

The review analyzed the anticancer evidence for endocannabinoids, phytocannabinoids, and synthetic cannabinoids across multiple cancer types including glioma, breast, prostate, liver, and lung cancer. Both in vitro (cell line) and in vivo (animal) studies showed cannabinoids could inhibit tumor growth through multiple mechanisms.

Key pathways included the ERK signaling pathway and ceramide/lipid signaling. An emerging area was the interplay between autophagy (cellular self-digestion) and apoptosis (programmed cell death) in cannabinoid-induced cancer cell killing. However, results remained contradictory, with some studies showing cannabinoids promoting rather than inhibiting tumor growth under certain conditions.

Why it matters

Cancer patients increasingly use cannabis alongside conventional treatment. Understanding whether cannabinoids genuinely have anticancer properties, and under what conditions they might help versus harm, is critical for informed decision-making and future drug development.

The numbers in context

Studies covered: glioma, breast, prostate, endothelial, liver, lung cancer. Key pathways: ERK signaling, ceramide signaling. Types of cannabinoids: endo-, phyto-, synthetic. Both pro- and anti-tumor effects documented depending on conditions.

How the study worked

Critical narrative review of preclinical cannabinoid anticancer research. Covered endo-, phyto-, and synthetic cannabinoids across multiple cancer types. Analyzed mechanisms of action including cell signaling pathways, autophagy, and apoptosis.

What this study cannot tell us

Most evidence was preclinical (cell lines and animal models). In vitro results often do not translate to in vivo efficacy. Contradictory findings across studies remained unresolved. The doses used in laboratory studies may not be achievable in the human body. Very few human clinical studies existed at the time.

How to read the evidence

Review of preclinical evidence; preliminary and contradictory across studies.

When this study was published

Published in 2013. Cannabinoid anticancer research has continued, with a small number of clinical trials beginning.

The bigger picture

The contradictory nature of the evidence highlights a fundamental challenge: cannabinoid effects on cancer cells are highly dependent on the specific compound, dose, duration, and cancer type. This complexity means blanket statements about cannabis "curing cancer" are not supported, but also means the therapeutic potential has not been dismissed.

Questions still open

  • Under what conditions do cannabinoids promote versus inhibit tumor growth? Can cannabinoid anticancer effects be harnessed without contradictory pro-tumor effects? Would cannabinoids work as adjuncts to conventional cancer treatments?

Common questions

Can cannabis cure cancer?
The evidence does not support this claim. While numerous laboratory studies show cannabinoids can kill cancer cells under specific conditions, results are contradictory (some conditions show tumor promotion), and almost all evidence comes from cell lines and animal models. The gap between killing cancer cells in a dish and treating cancer in humans is enormous.
Should cancer patients use cannabis?
Many cancer patients use cannabis for symptom management (pain, nausea, appetite). Whether cannabinoids have direct anticancer effects in humans remains unproven. The review emphasized that the contradictory preclinical evidence means cannabis should not replace conventional cancer treatment. Patients should discuss cannabis use with their oncology team.

Read the original research

Critical appraisal of the potential use of cannabinoids in cancer management.

Cancer management and research, 5, 301-13

Citation

Cridge, Belinda J; Rosengren, Rhonda J. (2013). Critical appraisal of the potential use of cannabinoids in cancer management.. Cancer management and research, 5, 301-13. https://doi.org/10.2147/CMAR.S36105

Explore the wider topic